Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Systemic Lupus Erythematosus: HELP
Articles by Frank Buttgereit
Based on 3 articles published since 2008

Between 2008 and 2019, F. Buttgereit wrote the following 3 articles about Lupus Erythematosus, Systemic.
+ Citations + Abstracts
1 Editorial Autoimmune rheumatic diseases. 2014

Anaya, Juan-Manuel / Shoenfeld, Yehuda / Buttgereit, Frank / Gonzalez-Gay, Miguel A. ·Center for Autoimmune Diseases Research (CREA), Universidad del Rosario, Carrera 24 No. 63C-69, 111221 Bogota, Colombia. · Zabludowitcz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Sackler Faculty of Medicine, Tel Aviv University, 52621 Tel-Hashomer, Israel. · Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Charitéplatz 1, 10117 Berlin, Germany. · Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Avenida de Valdecilla, s/n, Cantabria, 39008 Santander, Spain. ·Biomed Res Int · Pubmed #25162038.

ABSTRACT: -- No abstract --

2 Review [Bone densitometry in inflammatory rheumatic diseases : Characteristics of the measurement site and disease-specific factors]. 2009

Franck, H / Anonymous1210637 / Braun, J / Buttgereit, F / Demary, W / Hein, G / Kekow, J / Schett, G / Kern, P M. ·Schwerpunktpraxis Rheumatologie, Godesberger Allee 90, 53175, Bonn, Deutschland. Hgfranck@gmx.de ·Z Rheumatol · Pubmed #19714343.

ABSTRACT: Bone densitometry should be performed earlier in patients with inflammatory arthritis, since factors such as inflammation and drug therapy, in particular treatment with glucocorticoids, have an important impact on the development of osteoporosis. DXA (Dual energy X-ray Absorptiometry) is considered the gold standard for bone densitometry. According to the German guidelines for osteoporosis, bone densitometry plays a crucial role in the choice of therapy.In patients with rheumatoid arthritis, measurement of peripheral bone (forearm) density in addition to lumbar spine and hip is recommended, since local bone loss is pathognomonic for this disease. DXA measurements of the hand enable the diagnosis of juxtaarticular osteoporosis at an earlier stage; however, this has not yet been established in routine practise.Bone measurement in patients with ankylosing spondylitis can be performed in the lumbar spine and the hip at disease onset. In systemic lupus erythematosus, bone loss is more frequent in patients with high inflammatory activity. Patients with psoriasis arthritis frequently have osteoporosis in the case of a destructive development of the joints.

3 Article Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. 2012

Hoyer, Bimba F / Mumtaz, Imtiaz M / Loddenkemper, Konstanze / Bruns, Anne / Sengler, Claudia / Hermann, Kay-Geert / Maza, Sofiane / Keitzer, Rolf / Burmester, Gerd-Rüdiger / Buttgereit, Frank / Radbruch, Andreas / Hiepe, Falk. ·Department of Medicine (Clinic for Rheumatology and Clinical Immunology), Charité- Universitätsmedizin Berlin, Berlin, Germany. ·Ann Rheum Dis · Pubmed #21953334.

ABSTRACT: METHODS: B cell subsets in the peripheral blood of 17 patients with TA were analysed and compared with nine patients with active systemic lupus erythematosus (SLE) and nine healthy controls by flow cytometry. Based on these findings, three patients with active refractory TA were treated with B cell depletion therapy (BCDT) using monoclonal anti-CD20 antibodies (rituximab). RESULTS: The absolute number and frequency of peripheral blood CD19(+)/CD20(-)/CD27(high) antibody-secreting cells in patients with active TA was significantly higher than in healthy donors. As in active SLE, the majority of these cells are newly generated plasmablasts which significantly correlated with TA activity. Three patients with active refractory TA and expansion of plasmablasts were successfully treated with BCDT, which resulted in remission. CONCLUSION: Disturbances of B cell homeostasis may be critical in TA. Circulating plasmablasts could be a useful biomarker of disease activity and a tool for selecting appropriate candidates for BCDT. B cells and plasmablasts/plasma cells may therefore represent novel targets for effective therapies for TA.